Nuclear Medicine Cures Deadly Ovarian Cancer in Lab Test
Reston, VA-A new 225 Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperit...
Reston, VA-A new 225 Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225 Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the September issue of The Journal of Nuclear Medicine. Epithelial ovarian cancer is the most lethal ovarian cancer and frequently presents as advanced-stage disease, such as peritoneal carcinomatosis, where disease has spread throughout the peritoneal cavity.